Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06321380
Other study ID # 38RC23.0381
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date April 2024
Est. completion date October 2025

Study information

Verified date March 2024
Source University Hospital, Grenoble
Contact Amelie Bichon
Phone 0476728161
Email abichon@chu-grenoble.fr
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The aim of the present study is to investigate potential cognitive mechanisms contributing to working memory impairment in Alzheimer's disease and vascular dementia. The investigators consider a new hypothesis suggesting that difficulties in mobilizing maintenance strategies of information could explain this working memory deficit. More specifically, the investigators assume that patient groups will have difficulties in employing both refreshing and elaborative strategies during a working memory task (i.e., complex span task), as compared to a control group.


Description:

Working memory is considered as a central hub in human cognition. Good working memory capacities are fundamental for daily life. However, previous research has indicated that patients with Alzheimer's disease or vascular dementia have significant working memory impairment. Currently, there is no consensus on the cognitive mechanisms responsible for this deficit. Prior findings have highlighted that patients with Alzheimer's disease and/or vascular dementia demonstrate specific difficulties in dual-task situations. In this context, the investigators hypothesize that the continuous alternation between maintenance and processing phases involved in working memory could be impaired for these patients. Thus, the aim of the present study is to investigate if patients with Alzheimer's disease and/or vascular dementia can use maintenance strategies of information in working memory, as typically observed in individuals without cognitive impairments. To this end, the investigators propose a short working memory task in which they manipulate the opportunities to use refreshing strategies and elaborative strategies. The investigators expect that patients with Alzheimer's disease, vascular dementia, or mixed dementia will benefit less than healthy older adults from the increased opportunities to employ refreshing and elaboration. These difficulties could account for the impaired working memory performance associated with these diseases. In a second step, the investigators formulate distinctive hypotheses between patient sub-groups: - On the one hand, Alzheimer's disease is characterized by salient impairment of episodic long-term memory. Consequently, the investigators hypothesize that the working memory decline could be related to this deficit in long-term memory. Specifically, patients with Alzheimer's disease would have greater difficulty in implementing elaboration strategies. Thus, these patients' recall performance should benefit less from semantic links between the to-be-remembered items compared to patients with vascular dementia. - On the other hand, vascular dementia is characterized by a significant impairment of executive functioning. Thus, the investigators hypothesize that the working memory decline could be related to difficulties in implementing refreshing strategies (i.e., voluntary control of attention). Thus, the recall performance of these patients should benefit less from increased free time during the task, compared to patients with Alzheimer's disease. - Finally, very few studies have been carried out on patients with mixed dementia (from both Alzheimer's disease and vascular dementia). The investigators assume that the recall performance of these patients will benefit less from elaborative opportunities compared to patients with dementia vascular, and less from refreshing opportunities compared to patients with Alzheimer's disease.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 120
Est. completion date October 2025
Est. primary completion date September 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 65 Years and older
Eligibility Inclusion Criteria: - For patient and control groups: Adults = 65 years of age - For patient and control groups: Native French speaker - For patient and control groups: Vision for easy reading - For patient and control groups: Hearing for easy instruction understanding - For patient and control groups: Back span = 3 during the "Digit Span Backward" subtest (WAIS-IV) - For patient and control groups: Formulation of the non-opposition to participate in this study - For patient group only: Consultation in Grenoble University Hospital (Centre de Gérontologie Sud - Gerontology center) for clinical neuropsychological assessment due to suspected cognitive impairment - For patient group only: Diagnosis of Alzheimer's disease, vascular dementia, or mixed dementia (i.e., Alzheimer's disease and vascular dementia) - For patient group only: Have undergone a neuropsychological assessment at the day clinic, less than 6 months old. - For patient group only: Have obtained a medical opinion stating that there is no contraindication to participate in this study and no concurrent pathology that could impair the patient's cognitive abilities. - For patient group only: Absence of praxis and language disorders thath might prevent the carrying out of the experimental task. - For patient group only: MMSE score between 18 and 25 included - For control group only: External visitor/carer of a patient/resident of Grenoble University Hospital or volunteers at Grenoble University Hospital. - For control group only: MMSE score = 26 Exclusion Criteria: - For patient and control groups: People under guardianship or deprived of their freedom - For patient and control groups: Diagnosis of severe psychiatric disorders - For patient and control groups: Suspicion of pathologies related to alcohol dependence - For patient and control groups: No French social security coverage - For patient and control groups: Refusal to voluntarily participate in this study - For patient and control groups: People covered by articles L1121-5 to L1121-8 of the French Public Health Code - For patient group only: Suspicion of another neurodegenerative disease, such as fronto-temporal dementia, Parkinson's disease, Lewy body disease. - For patient group only: Clinical neuropsychological assessment did not reveal any cognitive impairment.

Study Design


Intervention

Behavioral:
Complex span task
The intervention consists in a computerized working memory task. This task follows the design of a complex span task, involving alternation between memorization and processing steps. For each trial, participants have to memorize French words. These words are sequentially displayed on the screen. Between each word, participants perform a processing task consisting in a spatial location task: They have to determine if a shape is at the top or at the bottom of the screen. After each processing episode, participants have a free time (i.e., available time to maintain information in WM). At the end of each trial, participants perform an orally immediate recall. This experimental task involves several conditions in order to manipulate the opportunities for the spontaneous use of refreshing and elaborative strategies.
Diagnostic Test:
Clinical neuropsychological assessment
As part of routine care, participants in the patient group undergo a standardized clinical neuropsychological assessment that evaluates several cognitive functions. The investigators hypothesize correlations between working memory performance during the experimental task and the results of neuropsychological tests. Thus, the investigators consider the results to several French versions of neuropsychological tests: MMSE (Mini-Mental State Examination) "Digit Span Backward" subtest (WAIS-IV) Stroop Test Trail Making Test (TMT) Rappel Libre - Rappel Indicé à 16 items or GERIA-12 Category fluences Instrumental Activities of Daily Living and ADL .
Clinical neurospychological assessement
Participants in the control group undergo 2 tests clinical that evaluate cognitive functioning. The investigators consider the results to French versions of these neuropsychological tests: MMSE (Mini-Mental State Examination; ) "Digit Span Backward" subtest (WAIS-IV)

Locations

Country Name City State
n/a

Sponsors (5)

Lead Sponsor Collaborator
University Hospital, Grenoble Centre National de la Recherche Scientifique, France, Laboratoire de Psychologie et NeuroCognition, Université Savoie Mont Blanc, University Grenoble Alps

References & Publications (27)

Baddeley AD, Baddeley HA, Bucks RS, Wilcock GK. Attentional control in Alzheimer's disease. Brain. 2001 Aug;124(Pt 8):1492-508. doi: 10.1093/brain/124.8.1492. — View Citation

Bartsch LM, Singmann H, Oberauer K. The effects of refreshing and elaboration on working memory performance, and their contributions to long-term memory formation. Mem Cognit. 2018 Jul;46(5):796-808. doi: 10.3758/s13421-018-0805-9. — View Citation

Bayard, S., Erkes, J., & Moroni, C. (2009). Test du Stroop Victoria-Adaptation Francophone. CPCN-LR, Gignac.

Belleville S, Chertkow H, Gauthier S. Working memory and control of attention in persons with Alzheimer's disease and mild cognitive impairment. Neuropsychology. 2007 Jul;21(4):458-69. doi: 10.1037/0894-4105.21.4.458. — View Citation

Belleville S, Peretz I, Malenfant D. Examination of the working memory components in normal aging and in dementia of the Alzheimer type. Neuropsychologia. 1996 Mar;34(3):195-207. doi: 10.1016/0028-3932(95)00097-6. — View Citation

Camos V, Johnson M, Loaiza V, Portrat S, Souza A, Vergauwe E. What is attentional refreshing in working memory? Ann N Y Acad Sci. 2018 Jul;1424(1):19-32. doi: 10.1111/nyas.13616. Epub 2018 Mar 15. — View Citation

Conway AR, Kane MJ, Bunting MF, Hambrick DZ, Wilhelm O, Engle RW. Working memory span tasks: A methodological review and user's guide. Psychon Bull Rev. 2005 Oct;12(5):769-86. doi: 10.3758/bf03196772. — View Citation

Craik, F. I. M., & Tulving, E. Depth of processing and the retention of words in episodic memory. Journal of Experimental Psychology (1975). General, 104, 268-294.

Foley JA, Cocchini G, Logie RH, Della Sala S. No dual-task practice effect in Alzheimer's disease. Memory. 2015;23(4):518-28. doi: 10.1080/09658211.2014.908922. Epub 2014 Apr 30. — View Citation

Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 Nov;12(3):189-98. doi: 10.1016/0022-3956(75)90026-6. No abstract available. — View Citation

Gagnon LG, Belleville S. Working memory in mild cognitive impairment and Alzheimer's disease: contribution of forgetting and predictive value of complex span tasks. Neuropsychology. 2011 Mar;25(2):226-36. doi: 10.1037/a0020919. — View Citation

Grober E., & Buschke H. . Genuine memory deficits in dementia. Developmental Neuropsychology,(1987) 5, 13-36.

Inasaridze K, Foley JA, Logie RH, Sala SD. Dual task impairments in vascular dementia. Behav Neurol. 2010;22(1-2):45-52. doi: 10.3233/BEN-2009-0252. — View Citation

Jahn H. Memory loss in Alzheimer's disease. Dialogues Clin Neurosci. 2013 Dec;15(4):445-54. doi: 10.31887/DCNS.2013.15.4/hjahn. — View Citation

Jellinger KA, Attems J. Prevalence and pathology of vascular dementia in the oldest-old. J Alzheimers Dis. 2010;21(4):1283-93. doi: 10.3233/jad-2010-100603. — View Citation

KATZ S, FORD AB, MOSKOWITZ RW, JACKSON BA, JAFFE MW. STUDIES OF ILLNESS IN THE AGED. THE INDEX OF ADL: A STANDARDIZED MEASURE OF BIOLOGICAL AND PSYCHOSOCIAL FUNCTION. JAMA. 1963 Sep 21;185:914-9. doi: 10.1001/jama.1963.03060120024016. No abstract available. — View Citation

Korczyn AD, Vakhapova V, Grinberg LT. Vascular dementia. J Neurol Sci. 2012 Nov 15;322(1-2):2-10. doi: 10.1016/j.jns.2012.03.027. Epub 2012 May 8. — View Citation

Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969 Autumn;9(3):179-86. No abstract available. — View Citation

Logie, R., Camos, V., & Cowan, N. Working memory: State of the science. Oxford University Press. (2020).

McGuinness B, Barrett SL, Craig D, Lawson J, Passmore AP. Executive functioning in Alzheimer's disease and vascular dementia. Int J Geriatr Psychiatry. 2010 Jun;25(6):562-8. doi: 10.1002/gps.2375. — View Citation

O'Brien JT, Thomas A. Vascular dementia. Lancet. 2015 Oct 24;386(10004):1698-706. doi: 10.1016/S0140-6736(15)00463-8. — View Citation

Raoux N, Le Goff M, Auriacombe S, Dartigues JF, Amieva H. [Semantic and letter fluency tasks: normative data in an elderly population of 70 years old and over from the PAQUID cohort]. Rev Neurol (Paris). 2010 Jun-Jul;166(6-7):594-605. doi: 10.1016/j.neurol.2010.01.012. Epub 2010 Mar 16. French. — View Citation

Roy, A., Fournet, N., Le Gall, D., Roulin, J. L. BRIEF. Inventaire d'évaluation comportementale des fonctions exécutive - Adaptation française. Hogrèfe France Editions (2014).

Tombaugh TN. Trail Making Test A and B: normative data stratified by age and education. Arch Clin Neuropsychol. 2004 Mar;19(2):203-14. doi: 10.1016/S0887-6177(03)00039-8. — View Citation

Vandenberghe M, Michiels J, Vanderaspoilden V, Claes T, Fery P. [Creation and normalisation of a verbal episodic memory task in elderly adults: "GERIA-12"]. Rev Neurol (Paris). 2015 Dec;171(12):853-65. doi: 10.1016/j.neurol.2015.08.001. Epub 2015 Nov 10. French. — View Citation

Vergauwe E, Ricker TJ, Langerock N, Cowan N. What do people typically do between list items? The nature of attention-based mnemonic activities depends on task context. J Exp Psychol Learn Mem Cogn. 2019 May;45(5):779-794. doi: 10.1037/xlm0000625. Epub 2018 Jul 19. — View Citation

Zheng C, Zhang RS, Wan T, Zhao JS. Topological Alterations of Working Memory Impairment in Aged Patients With Vascular Dementia. Front Aging Neurosci. 2021 Oct 4;13:741445. doi: 10.3389/fnagi.2021.741445. eCollection 2021. — View Citation

* Note: There are 27 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Primary Memory performance in the Working memory task Percentage of correct immediate recall, computed with strict serial recall criterion (item identity + correct position) and computed with item recall criterion (item identity only). 15 minutes
Primary Processing performance in the Working memory task Percentage of correct response in the spatial part of working memory task 15 minutes
Primary Reaction time Reaction time for each distractor (in ms) in the spatial part of working memory task 30 minutes
Secondary Mini-Mental State Examination (MMSE) MMSE is a test evaluate global cognitive functioning Score from 0 to 30 A higher score mean a better cognitive efficiency 15 minutes
Secondary Digit span forward WAIS IV (digit number) The participant's span is noted, corresponding to the longest number of sequential digits that can be repeated forward. 5 minutes
Secondary Digit span forward WAIS IV (standard note) This scale permitted to obtain a standard note from 0 to 19 A higher score means a better performance 5 minutes
Secondary Digit span backward WAIS IV (digit number) The participant's span is noted, corresponding to the longest number of sequential digits that can be repeated backward. 5 minutes
Secondary Digit span backward WAIS IV (standard note) This scale permitted to obtain a standard note from 0 to 19 A higher score means a better performance 5 minutes
Secondary Stroop Test - denomination part the denomination part of stroop test measures processing speed time is taken, in seconds 30 secondes
Secondary Stroop Test - minor interference part (Time) this part of stroop test measures low inhibition process time is taken, in seconds 30 secondes
Secondary Stroop Test - minor interference part (errors) this part of stroop test measures low inhibition process number of errors is noted, from 0 to 24 30 secondes
Secondary Stroop Test - major interference part (time) this part of stroop test measures strong inhibition process time is taken, in seconds 90 secondes
Secondary Stroop Test - major interference part (errors) this part of stroop test measures strong inhibition process number of errors is noted, from 0 to 24 90 secondes
Secondary Trail Making Test - Part A (time) This test evaluate motor speed processing Time in seconds 2 minutes
Secondary Trail Making Test - Part A (errors) This test evaluates motor speed processing Number of errors is noted 2 minutes
Secondary Trail Making Test - Part B (time) This test evaluates mental flexibility Time in seconds 5 minutes
Secondary Trail Making Test - Part B (errors) This test evaluates mental flexibility Number of errors is noted 5 minutes
Secondary Category fluences Number of correct words is noted 5 minutes
Secondary Memory evaluation (16-item Free and Cued Recall, or GERIA-12) These tests evaluate verbal episodic memory Scores are noted for each trail, from 0 to 16 (RL-RI/16) or 0 to 12 (Geria-12) A higher score means a better performance 40 minutes
Secondary Naming task This test evaluate the capacity to correctly name a picture Score is noted, from 0 to 40 A higher score means a better performance 40 minutes
Secondary Behavior rating inventory of executive function Questionnaire (french version) on patient's daily executive functioning, completed by a relative of the patient, if present Global score from 75 to 225, composing by several composite scores. A higher score means a more severe executive dysfonctionning in daily life 10 minutes
Secondary Instrumental Activities of Daily Living Questionnaire completed by a professional (nurse or doctor) with the patient and an accompagniant if present Score from 0 to 8 A higher score mean a better autonomy in daily life 5 minutes
Secondary Activities of Daily Living Questionnaire completed by a professional (nurse or doctor) with the patient and an accompagniant if present Score from 0 to 6 A higher score mean a better autonomy in daily life 5 minutes
See also
  Status Clinical Trial Phase
Completed NCT04044495 - Sleep, Rhythms and Risk of Alzheimer's Disease N/A
Completed NCT04079803 - PTI-125 for Mild-to-moderate Alzheimer's Disease Patients Phase 2
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT04520698 - Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease N/A
Active, not recruiting NCT04606420 - Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease N/A
Recruiting NCT05820919 - Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase N/A
Terminated NCT03672474 - REGEnLIFE RGn530 - Feasibility Pilot N/A
Completed NCT03430648 - Is Tau Protein Linked to Mobility Function?
Recruiting NCT04949750 - Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease N/A
Recruiting NCT04522739 - Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease Phase 4
Recruiting NCT05557409 - A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation Phase 3
Recruiting NCT05288842 - Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
Completed NCT06194552 - A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07 Phase 1
Completed NCT03239561 - Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants Early Phase 1
Completed NCT03184467 - Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients Phase 2
Active, not recruiting NCT03676881 - Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
Terminated NCT03487380 - Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Recruiting NCT05328115 - A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease Phase 1
Completed NCT05562583 - SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support N/A